CDK2 and gastric cancer: Inhibitors of NF-κB signaling, including IKKα/β inhibitors BAY11-7082 and BAY11-7085 demonstrated anti-proliferative (e.g., via suppressing cyclin A and cyclin-dependent kinase 2 (CDK-2) expression), pro-apoptotic (e.g., via down-regulation of Bcl-2, up-regulation of Bcl-2-associated X protein (Bax)), and anti-invasive abilities in GC cell lines and in xenograft models [166,167].